Abstracts tagged "Anakinra"

Abstract Number: 1923 • 2012 ACR/ARHP Annual Meeting
Biologics in Relapsing Polychondritis: A Single Center Case-Series
Guillaume Moulis¹, Laurent Sailler², Grégory Pugnet³, Leonardo Astudillo² and Philippe Arlet¹, ¹Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ³Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France
Background/Purpose: First-line treatment for relapsing polychondritis (RP) is costicosteroids (CS). Dapsone and methotrexate have been proposed as second-line therapies. Only few reports have been published…
Abstract Number: 747 • 2012 ACR/ARHP Annual Meeting
Familial Mediterranean Fever: Inhibition of IL-6 Signalling As a New Therapeutic Option in a Frequent Autoinflammatory Syndrome.
Nicola Stein¹, Matthias Witt², Michael Baeuerle³, Fabian Proft¹, Hendrik Schulze-Koops⁴ and Mathias Gruenke¹, ¹Rheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ²Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ³Division of Rheumatology, Klinikum Nürnberg, Nuernberg, Germany, ⁴University of Munich, Munich, Germany
Background/Purpose: Familial Mediterranean Fever (FMF) is the most prevalent episodic fever syndrome with more than 100.000 affected individuals worldwide. Colchicine is the established first-line therapy…
Abstract Number: 179 • 2012 ACR/ARHP Annual Meeting
Evaluation of Anakinra Therapy in Seven Adults After Suboptimal Response to Etanercept Therapy for Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome
Amanda K. Ombrello¹, Patrycja M. Hoffmann¹, Anne Jones¹, Karyl Barron² and Daniel L. Kastner¹, ¹Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²Div Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
Background/Purpose: Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome (TRAPS) is an autoinflammatory disease inherited in an autosomal dominant fashion. TRAPS develops secondary to mutations in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].